@article{JGO3100,
author = {Sidra Anwar and Wei Tan and Jinhee Yu and Alan Hutson and Milind Javle and Renuka Iyer},
title = {Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial},
journal = {Journal of Gastrointestinal Oncology},
volume = {5},
number = {6},
year = {2014},
keywords = {},
abstract = {Purpose: Pancreatic cancer is rapidly fatal with median survival of only 6 months (mo). Quality-of-life (QoL) was analyzed prospectively in a phase 2 study of gemcitabine (G), capecitabine (C) and bevacizumab (B) in APC patients.
Methods: A total of 50 patients with APC received B 15 mg/kg, C 1,300 mg/m2 daily for 2 weeks and G 1,000 mg/m2 weekly 2 times; cycles were repeated every 21 days. Endpoints: progression free survival (PFS), overall survival (OS) and assessment of QoL prior to each cycle using the European organization for research and treatment of cancer (EORTC) PAN-26 QoL questionnaire. An exact 95% confidence interval (CI) (Clopper-Pearson method) was used to assess rate of improved QoL (defined as >5 % decrease in two consecutive scores compared with baseline).
Results: Patient characteristics- Stage IIB/III/IV: 3/5/42; Sex: 28 M/22 F; Median age: 64 years. QoL in patients- improved: 56%, no improvement: 24%; unevaluable: 20%. Median PFS: 5.8 mo, OS: 9.8 mo. QoL improvement rate: 28/40=0.7 (95% CI: 0.53-0.83) in evaluable patients. Using QoL improvement rate, no significant difference was seen in patients with OS ≥6 mo compared to OS },
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/3100}
}